2021
Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer
McNamara B, Guerra R, Qin J, Craig A, Chen L, Varma M, Chapman J. Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer. Gynecologic Oncology Reports 2021, 38: 100870. PMID: 34646929, PMCID: PMC8496105, DOI: 10.1016/j.gore.2021.100870.Peer-Reviewed Original ResearchInterval cytoreductive surgeryProgression-free survivalAdvanced ovarian cancerBowel resectionCytoreductive surgeryOvarian cancerKaplan-Meier survival analysisThree-year survivalIncreased risk of mortalityLonger hospital stayCox proportional hazards modelsLong-term sequelaeRisk of mortalityProportional hazards modelInterval cytoreductionNeoadjuvant cyclesR0 resectionNeoadjuvant chemotherapyConfounding variables of ageASA scoreBlood transfusionHospital staySurvival impactPoor prognosisTumor RegistryA machine‐learning modified CART algorithm informs Merkel cell carcinoma prognosis
Cheraghlou S, Sadda P, Agogo GO, Girardi M. A machine‐learning modified CART algorithm informs Merkel cell carcinoma prognosis. Australasian Journal Of Dermatology 2021, 62: 323-330. PMID: 34028790, DOI: 10.1111/ajd.13624.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMerkel cell carcinomaPositive lymph node countLymph node countPositive nodesDistant metastasisValidation cohortRare neuroendocrine skin cancerRetrospective cohort studyEnd Results registryLymph node biopsyLymph node metastasisThree-year survivalNeuroendocrine skin cancerNovel prognostic factorHigh mortality rateNode countAJCC groupsMCC stagingSEER cohortCohort studyMCC patientsNode biopsyPrognostic factorsNode metastasisThree-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Moreno B, Sharon E, Cheever MA, Topalian SL. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. Journal For ImmunoTherapy Of Cancer 2021, 9: e002478. PMID: 33879601, PMCID: PMC8061836, DOI: 10.1136/jitc-2021-002478.Peer-Reviewed Original ResearchConceptsProgression-free survivalMerkel cell carcinomaSalvage therapyStable diseaseCell carcinomaBaseline Eastern Cooperative Oncology Group performance statusEastern Cooperative Oncology Group performance statusAnti-programmed death-1 therapyCell death-1 pathway inhibitorsDeath-1 pathway inhibitorsDurable progression-free survivalFirst-line pembrolizumab therapyMedian progression-free survivalMulticenter phase II trialRefractory Merkel cell carcinomaTumor progressionAdvanced Merkel cell carcinomaMedian response durationFirst-line pembrolizumabPhase II trialProportion of patientsInitial disease progressionThree-year survivalDurable tumor regressionOverall response rate
2018
Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry
Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, Karam V, Salizzoni M, Andujar RL, Fondevila C, De Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwaal K, Gonzales EM, Charco R, Zieniewicz K, De Carlis L, Duvoux C, Association A. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. Journal Of Hepatology 2018, 69: 810-817. PMID: 29940268, DOI: 10.1016/j.jhep.2018.06.010.Peer-Reviewed Original ResearchConceptsHepatitis C virusNon-alcoholic steatohepatitisHepatitis B virusEuropean Liver Transplant RegistryLiver transplantationSurvival of recipientsDAA eraLiver diseaseHepatocellular carcinomaEvolution of indicationsVirus infectionNumber of LTsHepatitis B virus infectionHepatitis C virus infectionAdult liver transplantationAdvent of DAAsImpact of DAAsLiver Transplant RegistrySecond-generation DAAsC virus infectionLiver transplant recipientsOutcomes of patientsB virus infectionThree-year survivalDAA treatment
2016
Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation
Azar MM, Malinis MF, Moss J, Formica RN, Villanueva MS. Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. International Journal Of STD & AIDS 2016, 28: 447-458. PMID: 27193421, DOI: 10.1177/0956462416651528.Peer-Reviewed Original ResearchConceptsInhibitor-based regimensRenal transplantationHIV/AIDSAntiretroviral regimenAntiretroviral therapyGraft survivalHIV-positive renal transplant recipientsEnd-stage renal diseaseHIV-positive patientsRenal transplant recipientsChronic kidney diseaseThree-year survivalInhibitor-based therapyNon-nucleoside reverseDrug-drug interactionsTransferase inhibitorsImmunosuppressive medicationsKidney transplantationTransplant recipientsAllograft rejectionGraft failureRenal diseaseCalcineurin inhibitorsClinical outcomesImmunosuppressive drugs
2012
The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC).
Haddad R, Rabinowits G, Tishler R, Adkins D, Khuri F, Clark J, Lorch J, Limaye S, Wirth L, O'Neill A, Riley S, Posner M. The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). Journal Of Clinical Oncology 2012, 30: 5501-5501. DOI: 10.1200/jco.2012.30.15_suppl.5501.Peer-Reviewed Original ResearchConcurrent chemoradiotherapyPhase III studyArm BIII studiesThree-year progression-free survivalMulticenter phase III studyCisplatin concurrent chemoradiotherapyLocally advanced headProgression-free survivalMedian Follow-UpSite of diseaseThree-year survivalASCO Annual MeetingNo survival differencePatterns of failurePattern of toxicityBoost radiotherapyOropharynx casesWeekly carboplatinWeekly docetaxelHPV statusArm APrimary endpointMedian ageAnalyzed patients
2004
Neuroendocrine Carcinomas of the Colon and Rectum
Bernick P, Klimstra D, Shia J, Minsky B, Saltz L, Shi W, Thaler H, Guillem J, Paty P, Cohen A, Wong W. Neuroendocrine Carcinomas of the Colon and Rectum. Diseases Of The Colon & Rectum 2004, 47: 163-169. PMID: 15043285, DOI: 10.1007/s10350-003-0038-1.Peer-Reviewed Original ResearchConceptsTime of diagnosisAmerican Joint Committee on CancerNeuroendocrine carcinomaMetastatic diseaseHigh-grade neuroendocrine carcinomaDiagnosis of neuroendocrine carcinomaMedian follow-up timeMarkers of neuroendocrine differentiationStudy group of patientsCell neuroendocrine carcinomaSmall cell carcinomaAverage patient ageThree-year survivalService databaseGroup of patientsNeuron-specific enolaseMedian survivalNeuroendocrine differentiationNeuroendocrine tumorsCarcinoid tumorsCell carcinomaNeuroendocrine markersPatient ageRectal cancerNo significant difference
1995
A comparison of two computer-based prognostic systems for AIDS.
Ohno-Machado L, Musen M. A comparison of two computer-based prognostic systems for AIDS. AMIA Annual Symposium Proceedings 1995, 737-41. PMID: 8563387, PMCID: PMC2579191.Peer-Reviewed Original ResearchConceptsCox modelPredictive valueCox proportional hazards modelDiagnosis of AIDSThree-year survivalProportional hazards modelCohort of peopleNegative predictive valuePositive predictive valueDisease progressionPrognostic accuracyStudy populationHazards modelIndividualized estimatesPrognostic toolProbability of survivalPatientsAIDSPrognostic systemCohortFirst yearDiagnosisDeathSurvivalYears
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply